Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 30.5× earnings vs its 53.7× historical median P/E.
Fair value ≈ $153.51 · price $87.34 today
Undervalued · 43% below
Loading valuation…
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
If you missed crypto and AI, peptides is your next change to catch an insane narrative unfolding. Don't get caught up in $HIMS, rather have a look at Bachem $BCHMF (swiss listing better under $BANB).
They supply to $NVO , $LLY and have around 25% of the market.
Pays a dividend. Swiss. Highly profitable and decades of history.
The two best things: Rarely discussed on X/Reddit and super small float available for retail (~15%). The founding family still owns 58%! The rest is locked in hands of institutions like the Norwegian Sovereign Wealth Fund.
This means the stock can move up fast and on small buys.
$CDXS VERY INTERESTING, AxoLabs is providing a lecture about Inclisiran at TIDES on May 12th? $BCHMF $NVS https://informaconnect.com/tides/speakers/ingo-rhl-phd/
$CDXS $ALNY $BCHMF If you haven't watched this video yet and are an investor here, or considering you should. It's very suggestive of what's upcoming in the near future in regards to AMVUTTRA (vutrisiran) with both Codexis and Bachem taking the reigns of manufacturing! https://www.bachem.com/knowledge-center/webinar-efficient-large-scale-sirna-manufacturing-enzymatic-ligation-of-short-rna-fragments/
$CDXS So what do we know as fact right now:
(1) Codexis is involved in with $MRK on the manufacturing of enlicitide (M-0616) through a biocatalytic process to produce trans-3-hydroxy-l-proline, a critical intermediate for synthesizing the oral PCSK9 inhibitor enlicitide decanoate (MK-0616), developed by Merck.
(2) Codexis and $BCHMF are involved with $ALNY through the manufacturing of Vutrisiran which is currently going through an FDA fast track for the treatment of patients with transthyretin-mediated amyloidosis with cardiomyopathy/ATTR-CM.
That right there ALONE makes this worth $ $3.50+.
MANY additional partnerships in the works!
$CDXS $BCHMF 17 March 2026
Bachem Reports Strong Sales Growth And Sustained High Profitability:
"Commercial production will be ramped up gradually in 2026 while the second construction phase is completed. The successful ramp-up of commercial production in Building K is a key prerequisite for achieving the sales target in 2026." https://www.bachem.com/knowledge-center/bachem-reports-strong-sales-growth-and-sustained-high-profitability/
Can you say, "vutrisiran aka Amvuttra"
